|
WO2019222850A1
|
|
Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
|
|
WO2019159005A2
|
|
Method of treating pain comprising repeated administrations of tetrodotoxin over time
|
|
CA2647235A1
|
|
Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
|
|
WO2007110220A1
|
|
USE OF 4,9-ANHYDRO-TETRODOTOXIN FOR THE TREATMENT OF DISEASES RELATED TO THE VOLTAGE-GATED SODIUM CHANNEL α SUBUNIT NAV 1.6
|
|
EP1931349A2
|
|
Use of sodium channel blockers for the management of musculoskeletal pain
|
|
US2010144767A1
|
|
Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
|
|
EP1882692A1
|
|
Dimethano-[1,3]dioxocino[6,5-D]pyrimidine-spiro derivatives of tetrodotoxin, process for their synthesis and uses thereof in the treatment of pain
|
|
EP1844783A1
|
|
Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel - subunit Nav1.6
|
|
EP1844782A1
|
|
Use of 4,9-anhydro-tetrodotoxin for the treatment of diseases related to the voltage-gated sodium channel subunit Nav1.6
|
|
EP1844781A1
|
|
Use of sodium channel blockers for the treatment of preterm labor
|
